Neuropathological role of PI3K/Akt/mTOR axis in Down syndrome brain

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1842, Issue 7, 2014, Pages 1144-1153

  Perluigi, Marzia ^a   Pupo, Gilda ^a   Tramutola, Antonella ^a   Cini, Chiara ^a   Coccia, Raffaella ^a   Barone, Eugenio ^a   Head, Elizabeth ^b   Butterfield, D Allan ^b,c   Di Domenico, Fabio ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Akt; Autophagy; Insulin signaling; mTOR; PI3K; Trisomy 21

Indexed keywords

AMYLOID BETA PROTEIN; BINDING PROTEIN; GLYCOGEN SYNTHASE KINASE 3; INSULIN RECEPTOR SUBSTRATE 1; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RCAN1 PROTEIN; REGULATOR PROTEIN; TAU PROTEIN; UNCLASSIFIED DRUG;

ADULT; ALZHEIMER DISEASE; ARTICLE; AUTOPHAGY; AUTOPSY; CONTROLLED STUDY; DEMENTIA; DOWN SYNDROME; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME REGULATION; FEMALE; FRONTAL CORTEX; HUMAN; HUMAN TISSUE; MALE; NEUROPATHOLOGY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

AKT; AUTOPHAGY; INSULIN SIGNALING; MTOR; PI3K; TRISOMY 21;

ADULT; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AUTOPHAGY; CASE-CONTROL STUDIES; DOWN SYNDROME; FEMALE; FRONTAL LOBE; HUMANS; INSULIN RECEPTOR SUBSTRATE PROTEINS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; MUSCLE PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; TAU PROTEINS; TOR SERINE-THREONINE KINASES; YOUNG ADULT;

EID: 84899787783     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2014.04.007     Document Type: Article

References (76)

1. Perluigi M., Butterfield D.A. Oxidative stress and down syndrome: a route toward Alzheimer-like dementia. Curr. Gerontol. Geriatr. Res. 2012, 2012:724904.
2. Cheon M.S., Dierssen M., Kim S.H., Lubec G. Protein expression of BACE1, BACE2 and APP in Down syndrome brains. Amino Acids 2008, 35:339-343.
3. Wisniewski K.E., Dalton A.J., McLachlan C., Wen G.Y., Wisniewski H.M. Alzheimer's disease in Down's syndrome: clinicopathologic studies. Neurology 1985, 35:957-961.
4. Wisniewski K.E., Wisniewski H.M., Wen G.Y. Occurrence of neuropathological changes and dementia of Alzheimers-disease in Down syndrome. Ann. Neurol. 1985, 17:278-282.
5. Schupf N., Sergievsky G.H. Genetic and host factors for dementia in Down's syndrome. Br. J. Psychiatry 2002, 180:405-410.
6. Leverenz J.B., Raskind M.A. Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis. Exp. Neurol. 1998, 150:296-304.
7. Cenini G., Dowling A.L., Beckett T.L., Barone E., Mancuso C., Murphy M.P., Levine H., Lott I.T., Schmitt F.A., Butterfield D.A., Head E. Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome. Biochim. Biophys. Acta 2012, 1822:130-138.
8. Perluigi M., di Domenico F., Fiorini A., Cocciolo A., Giorgi A., Foppoli C., Butterfield D.A., Giorlandino M., Giorlandino C., Schinina M.E., Coccia R. Oxidative stress occurs early in Down syndrome pregnancy: a redox proteomics analysis of amniotic fluid. Proteomics Clin. Appl. 2011, 5:167-178.
9. Sultana R., Perluigi M., Allan Butterfield D. Lipid peroxidation triggers neurodegeneration: a redox proteomics view into the Alzheimer disease brain. Free Radic. Biol. Med. 2013, 62:157-169.
10. Conti A., Fabbrini F., D'Agostino P., Negri R., Greco D., Genesio R., D'Armiento M., Olla C., Paladini D., Zannini M., Nitsch L. Altered expression of mitochondrial and extracellular matrix genes in the heart of human fetuses with chromosome 21 trisomy. BMC Genomics 2007, 8:268.
11. Lubec G., Engidawork E. The brain in Down syndrome (TRISOMY 21). J. Neurol. 2002, 249:1347-1356.
12. Di Domenico F., Coccia R., Cocciolo A., Murphy M.P., Cenini G., Head E., Butterfield D.A., Giorgi A., Schinina M.E., Mancuso C., Cini C., Perluigi M. Impairment of proteostasis network in Down syndrome prior to the development of Alzheimer's disease neuropathology: redox proteomics analysis of human brain. Biochim. Biophys. Acta 2013, 1832:1249-1259.
13. Ling D., Salvaterra P.M. A central role for autophagy in Alzheimer-type neurodegeneration. Autophagy 2009, 5:738-740.
14. Nixon R.A. Autophagy, amyloidogenesis and Alzheimer disease. J. Cell Sci. 2007, 120:4081-4091.
15. Zheng L., Marcusson J., Terman A. Oxidative stress and Alzheimer disease: the autophagy connection?. Autophagy 2006, 2:143-145.
16. Nixon R.A., Wegiel J., Kumar A., Yu W.H., Peterhoff C., Cataldo A., Cuervo A.M. Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study. J. Neuropathol. Exp. Neurol. 2005, 64:113-122.
17. Cai Z., Zhao B., Li K., Zhang L., Li C., Quazi S.H., Tan Y. Mammalian target of rapamycin: a valid therapeutic target through the autophagy pathway for Alzheimer's disease?. J. Neurosci. Res. 2012, 90:1105-1118.
18. O'Neill C. PI3-kinase/Akt/mTOR signaling: impaired on/off switches in aging, cognitive decline and Alzheimer's disease. Exp. Gerontol. 2013, 48:647-653.
19. Gupta A., Dey C.S. PTEN, a widely known negative regulator of insulin/PI3K signaling, positively regulates neuronal insulin resistance. Mol. Biol. Cell 2012, 23:3882-3898.
20. O'Neill C., Kiely A.P., Coakley M.F., Manning S., Long-Smith C.M. Insulin and IGF-1 signalling: longevity, protein homoeostasis and Alzheimer's disease. Biochem. Soc. Trans. 2012, 40:721-727.
21. Boura-Halfon S., Zick Y. Phosphorylation of IRS proteins, insulin action, and insulin resistance. Am. J. Physiol. Endocrinol. Metab. 2009, 296:E581-E591.
22. Craft S., Baker L.D., Montine T.J., Minoshima S., Watson G.S., Claxton A., Arbuckle M., Callaghan M., Tsai E., Plymate S.R., Green P.S., Leverenz J., Cross D., Gerton B. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch. Neurol. 2012, 69:29-38.
23. Griffin R.J., Moloney A., Kelliher M., Johnston J.A., Ravid R., Dockery P., O'Connor R., O'Neill C. Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology. J. Neurochem. 2005, 93:105-117.
24. Talbot K., Wang H.Y., Kazi H., Han L.Y., Bakshi K.P., Stucky A., Fuino R.L., Kawaguchi K.R., Samoyedny A.J., Wilson R.S., Arvanitakis Z., Schneider J.A., Wolf B.A., Bennett D.A., Trojanowski J.Q., Arnold S.E. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J. Clin. Invest. 2012, 122:1316-1338.
25. Fonseca C.T., Amaral D.M., Ribeiro M.G., Beserra I.C., Guimaraes M.M. Insulin resistance in adolescents with Down syndrome: a cross-sectional study. BMC Endocr. Disord. 2005, 5:6.
26. Dhand R., Hiles I., Panayotou G., Roche S., Fry M.J., Gout I., Totty N.F., Truong O., Vicendo P., Yonezawa K., Kasuga M., Courtneidge S.A., Waterfield M.D. Pi-3-kinase is a dual-specificity enzyme - autoregulation by an intrinsic protein-serine kinase-activity. EMBO J. 1994, 13:522-533.
27. Alessi D.R., Andjelkovic M., Caudwell B., Cron P., Morrice N., Cohen P., Hemmings B.A. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 1996, 15:6541-6551.
28. Lavallard V.J., Meijer A.J., Codogno P., Gual P. Autophagy, signaling and obesity. Pharmacol. Res. 2012, 66:513-525.
29. Ermak G., Davies K.J.A. Chronic high levels of the RCAN1-1 protein may promote neurodegeneration and Alzheimer disease. Free Radic. Biol. Med. 2013, 62:47-51.
30. Ermak G., Morgan T.E., Davies K.J. Chronic overexpression of the calcineurin inhibitory gene DSCR1 (Adapt78) is associated with Alzheimer's disease. J. Biol. Chem. 2001, 276:38787-38794.
31. Keating D.J., Dubach D., Zanin M.P., Yu Y., Martin K., Zhao Y.F., Chen C., Porta S., Arbones M.L., Mittaz L., Pritchard M.A. DSCR1/RCAN1 regulates vesicle exocytosis and fusion pore kinetics: implications for Down syndrome and Alzheimer's disease. Hum. Mol. Genet. 2008, 17:1020-1030.
32. Lloret A., Badia M.C., Giraldo E., Ermak G., Alonso M.D., Pallardo F.V., Davies K.J., Vina J. Amyloid-beta toxicity and tau hyperphosphorylation are linked via RCAN1 in Alzheimer's disease. J. Alzheimers Dis. 2011, 27:701-709.
33. Lott I.T., Head E., Doran E., Busciglio J. Beta-amyloid, oxidative stress and down syndrome. Curr. Alzheimer Res. 2006, 3:521-528.
34. Mann D.M.A. The pathological association between Down syndrome and Alzheimer-disease. Mech. Ageing Dev. 1988, 43:99-136.
35. Butterfield D.A., Swomley A.M., Sultana R. Amyloid beta-peptide (1-42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression. Antioxid. Redox Signal. 2013, 19:823-835.
36. Perluigi M., Butterfield D.A. The identification of protein biomarkers for oxidative stress in Down syndrome. Expert Rev. Proteomics 2011, 8:427-429.
37. Chen Z., Zhong C. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. Prog. Neurobiol. 2013, 108:21-43.
38. de la Monte S.M., Tong M., Nguyen V., Setshedi M., Longato L., Wands J.R. Ceramide-mediated insulin resistance and impairment of cognitive-motor functions. J. Alzheimers Dis. 2010, 21:967-984.
39. Pei J.J., Khatoon S., An W.L., Nordlinder M., Tanaka T., Braak H., Tsujio I., Takeda M., Alafuzoff I., Winblad B., Cowburn R.F., Grundke-Iqbal I., Iqbal K. Role of protein kinase B in Alzheimer's neurofibrillary pathology. Acta Neuropathol. 2003, 105:381-392.
40. Kwak Y.D., Ma T., Diao S.Y., Zhang X., Chen Y.M., Hsu J., Lipton S.A., Masliah E., Xu H.X., Liao F.F. NO signaling and S-nitrosylation regulate PTEN inhibition in neurodegeneration. Mol. Neurodegener. 2010, 5.
41. Sonoda Y., Mukai H., Matsuo K., Takahashi M., Ono Y., Maeda K., Akiyama H., Kawamata T. Accumulation of tumor-suppressor PTEN in Alzheimer neurofibrillary tangles. Neurosci. Lett. 2010, 471:20-24.
42. Zhang X., Li F., Bulloj A., Zhang Y.W., Tong G., Zhang Z., Liao F.F., Xu H. Tumor-suppressor PTEN affects tau phosphorylation, aggregation, and binding to microtubules. FASEB J. 2006, 20:1272-1274.
43. Siarey R.J., Kline-Burgess A., Cho M., Balbo A., Best T.K., Harashima C., Klann E., Galdzicki Z. Altered signaling pathways underlying abnormal hippocampal synaptic plasticity in the Ts65Dn mouse model of Down syndrome. J. Neurochem. 2006, 98:1266-1277.
44. Siddiqui A., Lacroix T., Stasko M.R., Scott-McKean J.J., Costa A.C., Gardiner K.J. Molecular responses of the Ts65Dn and Ts1Cje mouse models of Down syndrome to MK-801. Genes Brain Behav. 2008, 7:810-820.
45. Shah O.J., Wang Z.Y., Hunter T. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr. Biol. 2004, 14:1650-1656.
46. Tanti J.F., Jager J. Cellular mechanisms of insulin resistance: role of stress-regulated serine kinases and insulin receptor substrates (IRS) serine phosphorylation. Curr. Opin. Pharmacol. 2009, 9:753-762.
47. Li X., Alafuzoff I., Soininen H., Winblad B., Pei J.J. Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer's disease brain. FEBS J. 2005, 272:4211-4220.
48. Sun Y.X., Ji X., Mao X., Xie L., Jia J., Galvan V., Greenberg D.A., Jin K. Differential activation of mTOR complex 1 signaling in human brain with mild to severe Alzheimer's disease. J. Alzheimers Dis. 2014, 38(2):437-444.
49. Hosokawa N., Hara T., Kaizuka T., Kishi C., Takamura A., Miura Y., Iemura S., Natsume T., Takehana K., Yamada N., Guan J.L., Oshiro N., Mizushima N. Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy. Mol. Biol. Cell 2009, 20:1981-1991.
50. Bove J., Martinez-Vicente M., Vila M. Fighting neurodegeneration with rapamycin: mechanistic insights. Nat. Rev. Neurosci. 2011, 12:437-452.
51. Santos R.X., Correia S.C., Cardoso S., Carvalho C., Santos M.S., Moreira P.I. Effects of rapamycin and TOR on aging and memory: implications for Alzheimer's disease. J. Neurochem. 2011, 117:927-936.
52. Gual P., Le Marchand-Brustel Y., Tanti J.F. Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. Biochimie 2005, 87:99-109.
53. White M.F. Regulating insulin signaling and beta-cell function through IRS proteins. Can. J. Physiol. Pharmacol. 2006, 84:725-737.
54. Zick Y. Ser/Thr phosphorylation of IRS proteins: a molecular basis for insulin resistance. Sci. STKE 2005, 2005:e4.
55. Moloney A.M., Griffin R.J., Timmons S., O'Connor R., Ravid R., O'Neill C. Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol. Aging 2010, 31:224-243.
56. Craft S. Insulin resistance syndrome and Alzheimer's disease: age- and obesity-related effects on memory, amyloid, and inflammation. Neurobiol. Aging 2005, 26(Suppl. 1):65-69.
57. de la Monte S.M. Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. Curr. Alzheimer Res. 2012, 9:35-66.
58. Townsend M., Mehta T., Selkoe D.J. Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. J. Biol. Chem. 2007, 282:33305-33312.
59. Zhao W.Q., De Felice F.G., Fernandez S., Chen H., Lambert M.P., Quon M.J., Krafft G.A., Klein W.L. Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J. 2008, 22:246-260.
60. De Felice F.G., Vieira M.N., Bomfim T.R., Decker H., Velasco P.T., Lambert M.P., Viola K.L., Zhao W.Q., Ferreira S.T., Klein W.L. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:1971-1976.
61. Zhao W.Q., Townsend M. Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease. BBA Mol. Basis Dis. 2009, 1792:482-496.
62. Bomfim T.R., Forny-Germano L., Sathler L.B., Brito-Moreira J., Houzel J.C., Decker H., Silverman M.A., Kazi H., Melo H.M., McClean P.L., Holscher C., Arnold S.E., Talbot K., Klein W.L., Munoz D.P., Ferreira S.T., De Felice F.G. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated Abeta oligomers. J. Clin. Invest. 2012, 122:1339-1353.
63. Ma Q.L., Yang F., Rosario E.R., Ubeda O.J., Beech W., Gant D.J., Chen P.P., Hudspeth B., Chen C., Zhao Y., Vinters H.V., Frautschy S.A., Cole G.M. Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J. Neurosci. 2009, 29:9078-9089.
64. An W.L., Cowburn R.F., Li L., Braak H., Alafuzoff I., Iqbal K., Iqbal I.G., Winblad B., Pei J.J. Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease. Am. J. Pathol. 2003, 163:591-607.
65. Sheppard O., Plattner F., Rubin A., Slender A., Linehan J.M., Brandner S., Tybulewicz V.L., Fisher E.M., Wiseman F.K. Altered regulation of tau phosphorylation in a mouse model of down syndrome aging. Neurobiol. Aging 2012, 33(828):e831-e844.
66. Wang S., Wu J., Nie S.D., Bereczki E., Pei J.J. Dysregulated mTOR-dependent signaling in neurodegeneration or carcinogenesis: implication for Alzheimer's disease and brain tumors. J. Alzheimers Dis. 2013, 37:495-505.
67. Caccamo A., Magri A., Medina D.X., Wisely E.V., Lopez-Aranda M.F., Silva A.J., Oddo S. mTOR regulates tau phosphorylation and degradation: implications for Alzheimer's disease and other tauopathies. Aging Cell 2013, 12:370-380.
68. Lovestone S., Reynolds C.H. The phosphorylation of tau: a critical stage in neurodevelopment and neurodegenerative processes. Neuroscience 1997, 78:309-324.
69. Bhat R.V., Budd Haeberlein S.L., Avila J. Glycogen synthase kinase 3: a drug target for CNS therapies. J. Neurochem. 2004, 89:1313-1317.
70. Baki L., Shioi J., Wen P., Shao Z.P., Schwarzman A., Gama-Sosa M., Neve R., Robakis N.K. PS1 activates PI3K thus inhibiting GSK-3 activity and tau overphosphorylation: effects of FAD mutations. EMBO J. 2004, 23:2586-2596.
71. Hong M., Lee V.M.Y. Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. J. Biol. Chem. 1997, 272:19547-19553.
72. Liu F., Liang Z., Wegiel J., Hwang Y.W., Iqbal K., Grundke-Iqbal I., Ramakrishna N., Gong C.X. Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome. FASEB J. 2008, 22:3224-3233.
73. Wegiel J., Dowjat K., Kaczmarski W., Kuchna I., Nowicki K., Frackowiak J., Mazur Kolecka B., Silverman W.P., Reisberg B., Deleon M., Wisniewski T., Gong C.X., Liu F., Adayev T., Chen-Hwang M.C., Hwang Y.W. The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome. Acta Neuropathol. 2008, 116:391-407.
74. Dowjat W.K., Adayev T., Kuchna I., Nowicki K., Palminiello S., Hwang Y.W., Wegiel J. Trisomy-driven overexpression of DYRK1A kinase in the brain of subjects with Down syndrome. Neurosci. Lett. 2007, 413:77-81.
75. Ermak G., Pritchard M.A., Dronjak S., Niu B., Davies K.J.A. Do RCAN1 proteins link chronic stress with neurodegeneration?. FASEB J. 2011, 25:3306-3311.
76. Ermak G., Davies K.J. DSCR1(Adapt78) - a Janus gene providing stress protection but causing Alzheimer's disease?. IUBMB Life 2003, 55:29-31.